Investigating the role of immune responses in preventing relapse in women with high-grade serous ovarian cancer (HGSOC)

Development of novel diagnostic and prognostic clinical tests or models is critical to help stratify patients with ovarian cancer for an improved disease outcome, particular for a better survival and quality of life. This data presented herein give evidence that the diagnostic and prognostic prediction model for ovarian cancer patients can be improved by using inflammatory and immunosuppressive parameters, allowing for personalised therapy. We also identified the relationship between these novel biomarkers, which can be used in combination as potential anti-tumour targets in ovarian cancer, adding to the understanding of how these biomarkers co-exist within the tumour microenvironment.